Paliperidone Sandoz (Paliperidone Palmitate)

Paliperidone Sandoz is an atypical antipsychotic used in the management of schizophrenia and related psychotic disorders.

• Schizophrenia: Reduces the frequency and severity of psychotic episodes and helps maintain long‑term symptom control.
• Schizoaffective disorder: Alleviates both mood and psychotic symptoms when prescribed as part of a comprehensive treatment plan.
• Maintenance therapy after acute stabilization: Provides sustained drug levels to prevent relapse following successful acute phase treatment.

• Paliperidone Palmitate is a pro‑drug of paliperidone that slowly releases the active moiety after intramuscular injection. It antagonises dopamine D2 and serotonin 5‑HT2A receptors, modulating neurotransmission in pathways implicated in psychosis, and also exhibits moderate affinity for α‑adrenergic and histamine H1 receptors, contributing to its therapeutic profile.

Paliperidone Sandoz may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Injection site pain: localized discomfort at the administration site.
• Weight gain: gradual increase in body weight.
• Sedation: drowsiness or reduced alertness.
• Constipation: reduced bowel motility.
• Dry mouth: decreased salivation.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: rare but potentially life‑threatening reaction.
• Tardive dyskinesia: persistent involuntary movements.
• Hyperglycaemia: elevated blood glucose levels.
• Orthostatic hypotension: marked drop in blood pressure upon standing.
• Seizures: rare occurrence, especially in predisposed individuals.

When prescribing Paliperidone Sandoz, clinicians should consider several safety aspects.

• Cardiovascular monitoring: assess for QT prolongation and orthostatic hypotension.
• Metabolic screening: regularly check blood glucose and lipid profiles.
• Pregnancy and lactation: evaluate risk‑benefit ratio before use.
• Elderly patients: start at lower doses and monitor for sedation and falls.
• Drug‑interaction review: assess concomitant medications for additive CNS effects.
• Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Paliperidone Sandoz can interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors: may increase paliperidone exposure and risk of toxicity.
• QT‑prolonging agents: additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., benzodiazepines): may enhance sedation.
• Antihypertensives: potential for additive orthostatic effects.
• Antidiabetic drugs: may require dose adjustment due to metabolic changes.